Gain-of-function mutations in the IDH1 gene occurs in various human cancers, including colorectal cancer [71] and glioma [72], which disrupt NADPH homeostasis by consuming NADPH for 2-hydroxyglutarate (2-HG) synthesis. Here, IDH1 is linked to central nervous system cancer.